State Street Corp Purchases 43,700 Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB)

State Street Corp lifted its position in shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) by 12.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 383,248 shares of the biotechnology company’s stock after acquiring an additional 43,700 shares during the period. State Street Corp owned approximately 0.23% of Seres Therapeutics worth $363,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. Providence Wealth Advisors LLC lifted its stake in Seres Therapeutics by 49.5% during the second quarter. Providence Wealth Advisors LLC now owns 76,250 shares of the biotechnology company’s stock worth $58,000 after purchasing an additional 25,250 shares during the last quarter. Point72 DIFC Ltd bought a new stake in shares of Seres Therapeutics during the 2nd quarter worth $64,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Seres Therapeutics in the second quarter valued at about $92,000. Vontobel Holding Ltd. bought a new position in Seres Therapeutics in the third quarter valued at about $374,000. Finally, Charles Schwab Investment Management Inc. raised its stake in Seres Therapeutics by 42.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 748,718 shares of the biotechnology company’s stock worth $708,000 after acquiring an additional 222,771 shares in the last quarter. Institutional investors and hedge funds own 59.34% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on MCRB shares. Chardan Capital reaffirmed a “buy” rating and set a $1.25 price target on shares of Seres Therapeutics in a report on Wednesday, November 13th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $10.00 target price on shares of Seres Therapeutics in a research note on Thursday, November 14th. JPMorgan Chase & Co. cut Seres Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Thursday, October 24th. Finally, StockNews.com raised Seres Therapeutics from a “sell” rating to a “hold” rating in a report on Friday. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $5.08.

Seres Therapeutics Price Performance

MCRB opened at $0.91 on Friday. Seres Therapeutics, Inc. has a fifty-two week low of $0.54 and a fifty-two week high of $2.05. The company’s 50 day moving average price is $0.82 and its two-hundred day moving average price is $0.90. The firm has a market capitalization of $154.59 million, a price-to-earnings ratio of -3.94 and a beta of 2.07.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.